Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations
Free accessResearch articleFirst published online April, 2015
Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations
Genotype (gt)6 HCV is common amongst HCV-positive populations of the Asia–Pacific region but cell culture models for this gt have only recently been developed. Boceprevir (SCH503034) is a clinically available inhibitor of the HCV NS3 protein. We investigated the efficacy of boceprevir for inhibiting replication of a chimeric gt1b replicon encoding a gt6a NS3 protease and defined the development of mutations in the protease when boceprevir treatment was applied.
Methods
We constructed a chimeric gt1b subgenomic replicon encoding a gt6 NS3 protease (NS3p) sequence (gt6NS3p_gt1b). The boceprevir EC50 value against replication of this replicon was determined using quantitative reverse transcriptase PCR. Next-generation sequencing was used to identify nucleotide changes associated with boceprevir resistance. The replication capacities of chimeric replicons containing mutations associated with boceprevir resistance were determined by colony formation efficiency assays.
Results
The boceprevir EC50 value for the gt6NS3p_gt1b replicon was 535 ±79 nM. Boceprevir-resistant gt6NS3p_gt1b replicon cell lines could be selected and they demonstrated drug-associated amino acid changes that have previously been reported in other HCV gts. Interestingly, no mutations were observed at A156, a position defined for boceprevir resistance in gt1 NS3p, while mutation at N122, which is rarely reported in boceprevir-resistant gt1 proteases, was frequently observed. Re-introduction of these mutations into the chimeric replicon altered their replication capacity, ranging from complete abolishment of replication (A156T) to increasing replication capacity (V36A, N122S). This report provides the first characterization of gt6 HCV resistance to boceprevir.
Conclusions
A chimeric HCV replicon encoding gt6 NS3 protease is sensitive to boceprevir and develops drug-resistant mutations at amino acid sites previously reported for other gts. Mutation at N122 also appears to be associated with boceprevir resistance in the gt6 NS3 protease.
References
1.
ChenS.L., MorganT.R.The natural history of hepatitis C virus (HCV) infection.Int J Med Sci2006; 3: 47–52.
2.
ShepardC.W., FinelliL., AlterM.J.Global epidemiology of hepatitis C virus infection.Lancet Infect Dis2005; 5: 558–567.
3.
HnatyszynH.J.Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes.Antivir Ther2005; 10: 1–11.
4.
SievertW., AltraifI., RazaviH.A.A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.Liver Int2011; 31Suppl 2: 61–80.
5.
MalcolmB.A., LiuR., LahserF.SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.Antimicrob Agents Chemother2006; 50: 1013–1020.
6.
LinC., LinK., LuongY.P.In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.J Biol Chem2004; 279: 17508–17514.
7.
LohmannV., KörnerF., KochJ., HerianU., TheilmannL., BartenschlagerR.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science1999; 285: 110–113.
8.
WakitaT., PietschmannT., KatoT.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.Nat Med2005; 11: 791–796.
9.
PietschmannT., KaulA., KoutsoudakisG.Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.Proc Natl Acad Sci U S A2006; 103: 7408–7413.
10.
YiM., VillanuevaR.A., ThomasD.L., WakitaT., LemonS.M.Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells.Proc Natl Acad Sci U S A2006; 103: 2310–2315.
11.
SaeedM., GondeauC., HmweS.Replication of hepatitis C virus genotype 3a in cultured cells.Gastroenterology2013; 144: 56–58 e7.
12.
PengB., YuM., XuS.Development of robust hepatitis C virus genotype 4 subgenomic replicons.Gastroenterology2013; 144: 59–61 e6.
13.
YuM., PengB., ChanK.Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.Antimicrob Agents Chemother2014; 58: 2638–2646.
14.
ImhofI., SimmondsP.Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.J Virol2010; 84: 4597–4610.
15.
GottweinJ.M., ScheelT.K., JensenT.B., GhanemL., BukhJ.Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.Gastroenterology2011; 141: 1067–1079.
16.
LiY.P., RamirezS., HumesD., JensenS.B., GottweinJ.M., BukhJ.Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.Gastroenterology2014; 146: 812–821.e4.
17.
IkedaM., YiM., LiK., LemonS.M.Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.J Virol2002; 76: 2997–3006.
18.
EyreN.S., PhillipsR.J., BowdenS.Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells.J Hepatol2009; 51: 446–457.
19.
LindgreenS.AdapterRemoval: easy cleaning of next-generation sequencing reads.BMC Res Notes2012; 5: 337.
20.
LangmeadB., SalzbergS.L.Fast gapped-read alignment with Bowtie 2.Nat Methods2012; 9: 357–359.
21.
WilmA., AwP.P., BertrandD.LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets.Nucleic Acids Res2012; 40: 11189–11201.
22.
ProngayA.J., GuoZ., YaoN.Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.J Med Chem2007; 50: 2310–2318.
23.
ZhouZ., WangN., WoodsonS.E.Antiviral activities of ISG20 in positive-strand RNA virus infections.Virology2011; 409: 175–188.
24.
KriegerN., LohmannV., BartenschlagerR.Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.J Virol2001; 75: 4614–4624.
25.
TongX., BogenS., ChaseR.Characterization of resistance mutations against HCV ketoamide protease inhibitors.Antiviral Res2008; 77: 177–185.
26.
BinderJ., TetangcoS., WeinshankM.Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.Antiviral Res2011; 91: 102–111.
27.
TongX., ChaseR., SkeltonA., ChenT., Wright-MinogueJ., MalcolmB.A.Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Antiviral Res2006; 70: 28–38.
28.
FlintM., MullenS., DeatlyA.M.Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Antimicrob Agents Chemother2009; 53: 401–411.
29.
SusserS., WelschC., WangY.Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.Hepatology2009; 50: 1709–1718.
30.
WuS., KandaT., NakamotoS., ImazekiF., YokosukaO.Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review.World J Gastroenterol2013; 19: 8940–8948.
31.
LenzO., VerbinnenT., LinT.I.In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Antimicrob Agents Chemother2010; 54: 1878–1887.
32.
CentoV., MirabelliC., SalpiniR.HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.PLoS ONE2012; 7: e39652.
